Fascia Iliaca Compartment Block Versus Quadratus Lumborum Block in Total Hip Arthroplasty

Seoul National University

Status

Completed

Conditions

Nerve Block

Pain, Postoperative

Treatments

Procedure: quadratus lumborum block

Procedure: fascia iliaca compartement block

Study type

Interventional

Funder types

Other

Identifiers

NCT05228028

2112-062-1282

Details and patient eligibility

About

Patients undergoing total hip arthroplasty are randomly assigned to two groups (fascia iliaca compartement block [FICB] group or quadratus lumborum block [QLB] group). In the FICB group, ultrasound-guided suprainguinal FICB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is performed on the ipsilateral surgical side at the end of surgery. In the QLB group, ultrasound-guided anterior QLB (30 ml of 0.375% ropivacaine with 75 µg of epinephrine) is done on the ipsilateral surgical side at the end of surgery. A standardized multimodal analgesic regimen is used for postoperative pain control. The total use of opioids including patient-controlled analgesia and rescue analgesics is compared in both groups for 24 hours after surgery. The amount of opioids used is compared by conversion to oral morphine equivalent dose. Pain score at rest and movement during postoperative 24 hours, time to first request for analgesics, the incidence of side effects, patient satisfaction for pain control at postoperative 24 hours, quality of recovery at postoperative 24 hours, time to discharge readiness, and hospital length of stay are compared.

Enrollment

80 patients

Sex

All

Ages

19 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult patients between the ages of 19 and 70 undergoing total hip arthroplasty under spinal anesthesia
Be able to provide written consent to participate in clinical trials, understand the procedures of this clinical trial, and be able to properly fill out patient-reported questionnaires
ASA physical status classification 1-2

Exclusion criteria

ASA physical status classification 3-4
Patients who are contraindicated to nerve blocks (hypersensitivity to local anesthetics, infection at the injection site, etc.)
Patients with chronic pain and taking pain medications, antidepressants, and anticonvulsants
Other major medical or psychiatric conditions that will affect response to treatment
Refusal of intravenous patient-controlled analgesia
Patients determined to be unsuitable for this clinical trial by the researchers